| Brayden Mcbride, MD | |
|
5 E 400 N, Springville, UT 84663-1347 | |
| (801) 489-8464 | |
| (801) 798-8513 |
| Full Name | Brayden Mcbride |
|---|---|
| Gender | Male |
| Speciality | Family Practice |
| Experience | 16 Years |
| Location | 5 E 400 N, Springville, Utah |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1831363225 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | 4985132-1205 (Utah) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Canyon Home Care | Salt lake city, UT | Home health agency |
| Utah Valley Hospital | Provo, UT | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Canyon View Medical Group Llc | 9739084351 | 36 |
News Archive
Bacteria provide a well-known playground for scientists and the evolution of these earliest life forms has shed important perspective on potential therapies for some of the most common, deadly diseases. Researchers at Case Western Reserve University School of Medicine have now discovered that, the gas nitric oxide (NO), produced in all cells of the human body for natural purposes, plays a fundamental regulatory role in controlling bacterial function, via a signaling mechanism called S-nitrosylation (SNO), which binds NO to protein molecules.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, in first- and second-line treatment of Clostridium difficile infection, nearly 70 percent of surveyed infectious disease specialists and internists will use Optimer's fidaxomicin and nearly half will use Medarex/Merck's CDA1 and CDB1, one year after the launch of these agents. The lower recurrent/relapse rate associated with fidaxomicin and CDA1/CDB1 is the most influential attribute surveyed clinicians cite in their decisions to prescribe these emerging agents for CDI.
IsoRay, Inc. announced today that it has successfully shipped the first set of Cesium-131 brachytherapy seeds to a Canadian customer for the purpose of furthering research and development of Cesium-131 in Canada. Cesium-131 is currently approved by Health Canada for the treatment of low-risk prostate cancers and has been cleared by the US FDA for treatment of a wide variety of malignant disease (e.g. prostate, head and neck, brain, breast, lung, eye, etc.).
Led by six globally-recognized experts in cancer care, the organization known as CHILL, Cancer-related Hair Loss, International Leadership and Linkage, announced today an initiative to collect and track evidence-based patient information and clinical guidance.
Researchers at Case Western Reserve University School of Medicine will lead a national study determining if corneas transplanted up to two weeks after donor death work as well as corneas transplanted up to one week after donor death. The National Eye Institute has awarded a $12.3 million grant to support the work.
› Verified 4 days ago
| Entity Name | Ihc Health Services Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1629260880 PECOS PAC ID: 1850209420 Enrollment ID: O20031105000079 |
News Archive
Bacteria provide a well-known playground for scientists and the evolution of these earliest life forms has shed important perspective on potential therapies for some of the most common, deadly diseases. Researchers at Case Western Reserve University School of Medicine have now discovered that, the gas nitric oxide (NO), produced in all cells of the human body for natural purposes, plays a fundamental regulatory role in controlling bacterial function, via a signaling mechanism called S-nitrosylation (SNO), which binds NO to protein molecules.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, in first- and second-line treatment of Clostridium difficile infection, nearly 70 percent of surveyed infectious disease specialists and internists will use Optimer's fidaxomicin and nearly half will use Medarex/Merck's CDA1 and CDB1, one year after the launch of these agents. The lower recurrent/relapse rate associated with fidaxomicin and CDA1/CDB1 is the most influential attribute surveyed clinicians cite in their decisions to prescribe these emerging agents for CDI.
IsoRay, Inc. announced today that it has successfully shipped the first set of Cesium-131 brachytherapy seeds to a Canadian customer for the purpose of furthering research and development of Cesium-131 in Canada. Cesium-131 is currently approved by Health Canada for the treatment of low-risk prostate cancers and has been cleared by the US FDA for treatment of a wide variety of malignant disease (e.g. prostate, head and neck, brain, breast, lung, eye, etc.).
Led by six globally-recognized experts in cancer care, the organization known as CHILL, Cancer-related Hair Loss, International Leadership and Linkage, announced today an initiative to collect and track evidence-based patient information and clinical guidance.
Researchers at Case Western Reserve University School of Medicine will lead a national study determining if corneas transplanted up to two weeks after donor death work as well as corneas transplanted up to one week after donor death. The National Eye Institute has awarded a $12.3 million grant to support the work.
› Verified 4 days ago
| Entity Name | Canyon View Medical Group Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1477709772 PECOS PAC ID: 9739084351 Enrollment ID: O20031205000226 |
News Archive
Bacteria provide a well-known playground for scientists and the evolution of these earliest life forms has shed important perspective on potential therapies for some of the most common, deadly diseases. Researchers at Case Western Reserve University School of Medicine have now discovered that, the gas nitric oxide (NO), produced in all cells of the human body for natural purposes, plays a fundamental regulatory role in controlling bacterial function, via a signaling mechanism called S-nitrosylation (SNO), which binds NO to protein molecules.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, in first- and second-line treatment of Clostridium difficile infection, nearly 70 percent of surveyed infectious disease specialists and internists will use Optimer's fidaxomicin and nearly half will use Medarex/Merck's CDA1 and CDB1, one year after the launch of these agents. The lower recurrent/relapse rate associated with fidaxomicin and CDA1/CDB1 is the most influential attribute surveyed clinicians cite in their decisions to prescribe these emerging agents for CDI.
IsoRay, Inc. announced today that it has successfully shipped the first set of Cesium-131 brachytherapy seeds to a Canadian customer for the purpose of furthering research and development of Cesium-131 in Canada. Cesium-131 is currently approved by Health Canada for the treatment of low-risk prostate cancers and has been cleared by the US FDA for treatment of a wide variety of malignant disease (e.g. prostate, head and neck, brain, breast, lung, eye, etc.).
Led by six globally-recognized experts in cancer care, the organization known as CHILL, Cancer-related Hair Loss, International Leadership and Linkage, announced today an initiative to collect and track evidence-based patient information and clinical guidance.
Researchers at Case Western Reserve University School of Medicine will lead a national study determining if corneas transplanted up to two weeks after donor death work as well as corneas transplanted up to one week after donor death. The National Eye Institute has awarded a $12.3 million grant to support the work.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Brayden Mcbride, MD 5 E 400 N, Springville, UT 84663-1347 Ph: (801) 489-8464 | Brayden Mcbride, MD 5 E 400 N, Springville, UT 84663-1347 Ph: (801) 489-8464 |
News Archive
Bacteria provide a well-known playground for scientists and the evolution of these earliest life forms has shed important perspective on potential therapies for some of the most common, deadly diseases. Researchers at Case Western Reserve University School of Medicine have now discovered that, the gas nitric oxide (NO), produced in all cells of the human body for natural purposes, plays a fundamental regulatory role in controlling bacterial function, via a signaling mechanism called S-nitrosylation (SNO), which binds NO to protein molecules.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, in first- and second-line treatment of Clostridium difficile infection, nearly 70 percent of surveyed infectious disease specialists and internists will use Optimer's fidaxomicin and nearly half will use Medarex/Merck's CDA1 and CDB1, one year after the launch of these agents. The lower recurrent/relapse rate associated with fidaxomicin and CDA1/CDB1 is the most influential attribute surveyed clinicians cite in their decisions to prescribe these emerging agents for CDI.
IsoRay, Inc. announced today that it has successfully shipped the first set of Cesium-131 brachytherapy seeds to a Canadian customer for the purpose of furthering research and development of Cesium-131 in Canada. Cesium-131 is currently approved by Health Canada for the treatment of low-risk prostate cancers and has been cleared by the US FDA for treatment of a wide variety of malignant disease (e.g. prostate, head and neck, brain, breast, lung, eye, etc.).
Led by six globally-recognized experts in cancer care, the organization known as CHILL, Cancer-related Hair Loss, International Leadership and Linkage, announced today an initiative to collect and track evidence-based patient information and clinical guidance.
Researchers at Case Western Reserve University School of Medicine will lead a national study determining if corneas transplanted up to two weeks after donor death work as well as corneas transplanted up to one week after donor death. The National Eye Institute has awarded a $12.3 million grant to support the work.
› Verified 4 days ago
Dr. Michael S Mclay, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 5 E 400 N, Springville, UT 84663 Phone: 801-489-8464 Fax: 801-489-6378 | |
William David Voss, DO Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 376 E 400 S, Springville, UT 84663 Phone: 801-491-9355 Fax: 801-491-3000 | |
Stephen Takasaki, DO Family Medicine Medicare: Medicare Enrolled Practice Location: 5 E 400 N, Springville, UT 84663 Phone: 801-489-8464 Fax: 801-798-8513 | |
Dr. Edward William Jackson, MD Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 786 S Left Hand Fork Hobble Creek Cyn, Springville, UT 84663 Phone: 801-489-9381 | |
Ian Mcmaster, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 672 W. 400 S., Suite 101, Springville, UT 84663 Phone: 801-491-9883 Fax: 801-489-3141 | |
Russell Beckstead, D.O. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 5 E 400 N, Springville, UT 84663 Phone: 801-489-8464 Fax: 801-798-8513 | |
Don L Bowcut, MD Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 385 S 400 E, Springville, UT 84663 Phone: 801-489-3244 |